These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Preparation and characterization of a single chain antibody fragment of mAb SZ-21 against platelets GPIIIa].
    Author: An G, Dong N, Shao B, Zhu M, Ruan C.
    Journal: Zhonghua Xue Ye Xue Za Zhi; 2002 Sep; 23(9):480-2. PubMed ID: 12482360.
    Abstract:
    OBJECTIVE: To prepare a single chain antibody (ScFv) of mAb SZ-21 against platelet GPIIIa for its future clinical application. METHODS: The expression vector pET20b-SZ-21ScFv was constructed and the fusion protein was expressed in E. coli BL21 (DE3) PlysS. The activated fusion protein was obtained after a series of purification steps, including cell breakage, inclusion body solubilization, His-bind resin affinity chromatography and protein refolding. RESULTS: The fusion protein yields were up to 21% of the total amount of bacteria protein. The ScFv fragment could inhibit ADP-induced platelets aggregation in a dose-dependent manner in vitro and the maximal inhibition rate was obtained at a concentration of 20 micro g/ml. It also reacted with endothelial cells as detected by flow cytometry. Moreover, the ScFv fragment was able to inhibit the binding of fibrinogen to platelet. CONCLUSION: The SZ-21ScFv fragment had the activity to inhibit platelets aggregation and the binding of fibrinogen to platelet, being potentially useful for the treatment of thrombotic diseases.
    [Abstract] [Full Text] [Related] [New Search]